Bardy Diagnostics, Inc., a Seattle, WA-based provider of ambulatory cardiac monitoring technologies and custom data solutions, raised $35.5m in Series B funding.
The round was led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures, and Rex Health Ventures and existing investors SV Health Investors, Health Enterprise Partners, and Ascension Ventures.
In conjunction with the funding, Rik Vandevenne, Managing Director of River Cities Capital Funds, and Garheng Kong, Managing Director of HealthQuest Capital, will join BardyDx’ board of directors.
The company intends to use the funds to further accelerate growth of its innovative P-wave focused cardiac monitoring platform through expansion of the sales force and monitoring services, and to support advanced development programs, including augmented intelligence and visualization technologies.
Led by Gust H. Bardy, MD, Founder and Chief Executive Officer, and Mark Handfelt, Chief Operating Officer, BardyDx provides Carnation Ambulatory Monitor, a P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device designed to improve patient compliance for adults and children weighing more than 10kg (22lbs). The CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis.